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Abstract
Purpose—Chemokines are implicated in T cell trafficking. We mapped the chemokine landscape 
in advanced stage ovarian cancer and characterized the expression of cognate receptors in 
autologous DC-vaccine primed T cells in the context of cell-based immunotherapy.
Experimental design—The expression of all known human chemokines in patients with 
primary ovarian cancer was analyzed on two independent microarray datasets and validated on 
tissue microarray. Peripheral blood T cells from five HLA-A2 patients with recurrent ovarian 
cancer, who previously received autologous tumor DC vaccine, underwent CD3/CD28 
costimulation and expansion ex vivo. Tumor-specific T cells were identified by HER2/neu 
pentamer staining and were evaluated for the expression and functionality of chemokine receptors 
important for homing to ovarian cancer.
Results—The chemokine landscape of ovarian cancer is heterogeneous with high expression of 
known lymphocyte-recruiting chemokines (CCL2, CCL4 and CCL5) in tumors with intraepithelial 
T cells, whereas CXCL10, CXCL12 and CXCL16 are expressed quasi-universally, including in 
tumors lacking tumor infiltrating T cells. DC-vaccine primed T cells were found to express the 
cognate receptors for the above chemokines. Ex vivo CD3/CD28 costimulation and expansion of 
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vaccine-primed T cells upregulated CXCR3 and CXCR4, and enhanced their migration toward 
universally expressed chemokines in ovarian cancer.
Conclusions—DC-primed tumor specific T cells are armed with the appropriate receptors to 
migrate towards universal ovarian cancer chemokines, and these receptors are further upregulated 
by ex vivo CD3/CD28 costimulation, which render T cells more fit for migrating towards these 
chemokines.
Introduction
Despite therapeutic advances in the treatment of ovarian cancer, survival of patients with late 
stage disease remains low. Increased infiltration of cytotoxic T cells in tumor islets 
correlates with significantly longer survival (1), while increased numbers of 
immunosuppressive cells such as CD4+CD25+FoxP3+ regulatory T cells (Treg) or B7-H4 
expressing tumor macrophages predict poor survival (2, 3). Our group has focused on 
autologous whole tumor lysate dendritic cell (DC)-based immune therapy strategies for 
patients with recurrent ovarian cancer. In a recent pilot clinical trial (UPCC-11807), patients 
showed clinical benefit from a personalized vaccine manufactured with freeze-thawed lysate 
of autologous tumor cells pulsed on autologous DCs after they were pretreated with 
systemic anti-VEGF antibody bevacizumab and oral metronomic cyclophosphamide (4). In 
addition to clinical benefit, in four out of six patients, a significant increase in circulating 
tumor-reactive T-cells was detected after vaccination. Furthermore, vaccine-primed T cells 
expanded efficiently in response to CD3/CD28 bead stimulation ex vivo while retaining 
tumor-reactive specificities. Following completion of this clinical trial, patients who had not 
progressed but had residual measurable disease, received an infusion of 5x109 of autologous 
vaccine-primed, ex vivo CD3/CD28 costimulated peripheral blood T-cells. Importantly, 
tumor-reactive T-cells reconstituted effectively in vivo after adoptive transfer and resulted in 
complete response in one patient and stable disease in another (4).
Following further optimization of the DC vaccine (5), we next opened a clinical trial for 
recurrent stage III/IV ovarian cancer (UPCC19809, NCT01132014) (6). In this trial, subjects 
are vaccinated five times intranodally with autologous DCs loaded with HOCl-oxidized 
autologous tumor lysate in combination with bevacizumab, low-dose cyclophosphamide and 
therapeutic dose acetyl salicylic acid (ASA) to inhibit tumor VEGF, attenuate Treg cells, and 
suppress tumor prostaglandin production, respectively. Preliminary results show that 
vaccination produces clinical benefit, which correlates with the induction of anti-tumor 
immune response (7). Following DC vaccination, patients undergo apheresis to collect 
vaccine primed Tcells, retaining the option to enrol in a subsequent adoptive T cell therapy 
study (UPCC-26810, NCT01312376) using ex vivo CD3/CD28 costimulated autologous 
vaccine-primed T-cells, in an attempt to boost the efficacy of the autologous cancer vaccine.
Successful immunotherapy depends on the ability of T cells to home into tumors. Infiltration 
of tumors by T cells is a complex multistep process involving adhesive interactions with 
vascular cells and migration within the stroma, much of which is regulated by chemotactic 
gradients (8, 9). Chemokines are structurally similar chemotactic cytokines, with 
overlapping receptor specificity and functions (10–12) and have a multifaceted role in tumor 
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biology (13–16). The chemokine landscape of the tumor microenvironment may differ 
significantly among tumors, and can affect immune cell composition, tumor growth and 
metastasis (17). Since leukocyte infiltration into tumors is controlled by chemokine 
gradients in the tumor microenvironment and cognate chemokine receptors expressed on 
immune cells (13, 18–20), decreased expression of appropriate chemokines can contribute to 
a lack of effector T cell infiltration and resistance to immunotherapy (21). Thus, successful 
immunotherapy should achieve an optimal match between the chemokine landscape of 
targeted tumors and the chemokine receptor repertoire expressed by the elicited effector T 
cells.
The heterogeneity of tumors with respect to their chemokine expression represents a major 
challenge to overcome. For example, although tumors with pre-existing intraepithelial T cell 
infiltrate exhibit a microenvironment that is conducive to T cell accumulation, tumors 
lacking T cells at the steady state could be resistant to immunotherapy. Considering that 
vascular normalization and reduction of Tregs would be two important maneuvers to 
enhance T cell homing in tumors and the impact of immunotherapy, we have designed a 
clinical trial that combines the optimized DC vaccine with low-dose cyclophosphamide and 
bevacizumab (4, 6). However, it remains uncertain whether the chemokines expressed by 
these tumors can pair with the chemokine receptors expressed by tumor-reactive T cells 
generated by immunotherapy and thus remains a potentially important issue in the design of 
effective immunotherapeutic strategies.
This study aimed to map the chemokine microenvironment in advanced stage papillary 
serous ovarian cancer in order to understand the requirements for chemokine receptor 
expression by tumor-reactive T cells. We also sought to characterize the chemokine 
receptors expressed by peripheral blood T lymphocytes after DC vaccination and after ex 
vivo CD3/CD28 costimulation in preparation for adoptive transfer. We found that ovarian 
cancers, including tumors lacking intraepithelial T cells, express specific lymphocyte 
attracting chemokines, such as CXCL10 and CXCL12, which are quasi-universally prevalent 
across patients and across tumor sites within patients. Importantly, vaccine-primed tumor-
specific peripheral blood T cells expressed functional cognate receptors for these 
chemokines, which enabled them to migrate towards these common ovarian cancer 
chemokines. Furthermore, CD3/CD28 costimulation of vaccine-primed T cells significantly 
enhanced the expression of the relevant chemokine receptors and augmented the migration 
of vaccine-induced tumor-specific T cells to the common ovarian cancer chemokines.
Materials and methods
Gene expression analysis
To analyze chemokine expression patterns in ovarian cancer, we performed gene expression 
profiling on 63 stage III–IV papillary serous primary (but not metastatic) ovarian cancer 
samples resected during debulking at the University of Turin, Italy. The clinicopathological 
characteristics of patients in this cohort are presented in Table 1. All patients received 
standard platinum-taxane based chemotherapy. Gene-expression profiling was performed 
using Affymetrix GeneChip® Human Gene ST 1.0 Arrays (GSE62873) as previously 
described (22). Publicly available Affymetrix array expression data set (GSE9891) covering 
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222 matching patients with papillary serous ovarian cancer (with similar clinicopathological 
characteristics – Table 1) from the Australian Ovarian Cancer Study was used as a validation 
cohort (23). Following normalization, technical outlier samples were identified and 
excluded.
Gene expression analysis was also performed on 13 primary and established human ovarian 
cancer cell lines using Affymetrix GeneChip® Human Gene ST 1.0 Arrays (GSE63553). 
OV7M and OV95 primary ovarian cancer cell lines were provided by Dr. Richard Carroll at 
the University of Pennsylvania (UPENN) and were derived from ovarian cancer patients as 
described (24). All other cell lines (A2008, OAW42, OVCAR2, OVCAR3, OVCAR4, 
OVCAR5, OVCAR8, OVCAR10, PE01, PE04, SKOV3) were obtained from the Ovarian 
Cancer Research Center cell bank at UPENN with documented and cited origin, thus were 
not re-authenticated at the time of the study (25). The detailed origin and characteristics of 
the cell lines are listed in Supplementary table I.
Tissue microarrays construction
A tissue microarray (TMA) was constructed at the Department of Pathology at UPENN 
from 50 treatment-naive patients with stage IIIC or IV papillary serous ovarian cancer who 
underwent primary resection at UPENN between 2005 and 2008, and whose clinical 
characteristics were similar to the two cohorts of patients used in the microarray data 
analysis (Table 1). Both primary tumor samples and matched metastatic deposits from the 
same patients were included in the TMA, as previously reported (26). Briefly, a total of 207 
tumor sites were represented on the array with a mean of 3.8 sites per patient, including one 
or two ovarian sites and one to seven metastatic sites. TMA blocks were selected by a 
trained pathologist. For each block, triplicate 0.6-mm cores of tumor were placed on a TMA 
slide using a manual arrayer.
Immunohistochemistry and TMA Scoring
Commercially available chemokine antibodies were validated and titrated on positive (i.e 
lymph node, prostate, lung or colon cancer) and negative control tissues (i.e cerebellum, 
stomach or testis) - as recommended by the manufacturers and described in the literature - 
prior to immunohistochemical analysis of the TMA samples. TMA immunostaining was 
performed with the following antibody clones: CCL2 (HPA019163, Sigma-Aldrich), CCL4 
(1738-1, Epitomics), CCL5 (AF-278-NA, R&D Systems), CCL28 (MAB7171, R&D 
Systems), CXCL10 (ab9807, Abcam), CXCL12 (SC-28876, Santa Cruz), CXCL16 
(ab101404, Abcam), CX3CL1 (HPA040361, Sigma-Aldrich). Lymphocytes were stained for 
CD3 (0452, Dakocytomation), CD8 (C8/144B, M7103, Dakocytomation) and FoxP3 (206D, 
320102, Biolegend).
Tumor cores were imaged using Aperio ImageScope and were independently scored at 20X 
magnification by two experienced pathology observers (RF and MDF) who were blinded to 
clinical and pathological parameters. An H-score was calculated by using intensity (score of 
3: strongly staining, score of 2: moderately staining, score of 1: weakly staining, score of 0: 
no staining) x percentage of tumor tissue stained (score of 1: 0–25%, score of 2: 26–50%, 
score of 3: 51–75%, score of 4: 76–100%) for each core (maximum score was 12). When 
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multiple fields were available for review, the median of their scores was recorded for that 
core. In the few cases where there was a discrepancy, a review was performed and a 
consensus reached. The immunostained microarrays were also scored for tumor-infiltrating 
lymphocytes (TIL) by an experienced pathologist (ISH). Lymphocytes infiltrating the tumor 
islets (i.e. the malignant epithelial compartment) and stromal lymphocytes (all other 
lymphocytes) were graded according to the following quantitative criteria: 0 - absent; 1 - 
rare [1–10/400x high-power field (hpf)]; 2 - moderate (11–20/hpf); 3 - numerous (>20/hpf). 
The lymphocyte density in partial/incomplete fields was normalized based on a visual 
assessment of the percentage that consisted of tumor epithelium or stroma.
Procurement of T cells from ovarian cancer subjects undergoing vaccination 
(UPCC-19809) followed by adoptive T cell transfer in (UPCC-26810)
We analyzed T cells from five HLA-A*0201 subjects with recurrent ovarian cancer, who 
were enrolled in a phase-I clinical protocol at UPENN UPCC-19809 (NCT01132014) and 
administered therapeutic vaccination using autologous DCs loaded in vitro with oxidized 
autologous tumor lysate. Vaccine-primed peripheral blood T cells were obtained in all 
subjects as part of study procedures through apheresis 10–15 days after the 4th or 5th 
vaccination. A ~15L apheresis was performed at the Apheresis Unit of the Hospital of the 
University of Pennsylvania (HUP). Cells were transferred fresh to the Clinical Cell and 
Vaccine Production Facility (CVPF) at HUP where they were washed to remove plasma, 
platelets and red blood cell contamination using the Baxter CytoMate or Haemonetics 
CellSaver5 with X-VIVO™ 15 based media (Lonza, Walkersville, MD). T cells were 
isolated by counterflow centrifugal elutriation (Terumo ElutraTM Cell Separation System) 
to eliminate monocyte contamination. Cells were then counted and cryopreserved in liquid 
nitrogen vapor phase in cryopreservation media containing 10% DMSO.
Following completion of vaccination, the same subjects as above were enrolled in a follow-
on phase I clinical protocol at UPENN (UPCC-26810, NCT01312376) administering 
adoptive transfer of ex vivo CD3/CD28 costimulated vaccine-primed autologous peripheral 
blood T cells. Elutriated vaccine-primed T cells were thawed and seeded into gas permeable 
flasks in X-VIVO™ 15 media supplemented with 5% pooled human AB serum. Anti-CD3/
anti-CD28 antibody-coated Dynal microbeads were added at a ratio of 3:1 beads to cell. To 
maintain appropriate T cell density, fresh media with low level of IL-2 (100 IU/ml) was 
added throughout the 11 day expansion. Cells were then harvested for adoptive transfer, 
while aliquots were cryopreserved after microbead removal. For this study, we analyzed 
freshly thawed elutriated T cells from the apheresis product (vaccine-primed T cells) as well 
as freshly thawed CD3/CD28 costimulated T cells.
Chemotaxis assays
T cells number and viability was assessed using Guava Viacount reagent followed by 
quantitative capillary flow cytometry (Millipore Guava). Cells were rested in fresh media 
(RPMI 1640, Mediatech) supplemented with 10% FBS, 100 IU/ml penicillin, 100 mg/ml 
streptomycin and 20 IU/ml IL-2 for 24 hours prior to the chemotaxis assay. Following assay 
optimization and manufacturers’ guidelines, the following chemokines were plated either 
alone or in combinations on the bottom of Corning plate: 10 ng/ml CCL28 (SRP3112, 
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Sigma-Aldrich), 50 ng/ml CXCL10 (300-12, Peprotech) and 100 ng/ml CXCL12 (300-28A, 
Peprotech). Vaccine primed and costimulated T cells were seeded at a concentration of 
3-5x105 cells at the top transwell migration chamber (Corning HTS Transwell®-96, 5 μm 
pore polycarbonate membrane). The average number of live loaded CD3+ cells was 
determined by cell counter for each patient. After 3 hours of migration the total number of 
migrated CD3+ was counted and these cells were further analyzed for CD4, CD8 or 
HER2/neu expression by flow cytometry. All experiments were performed in duplicates and 
repeated in three independent experiments. Results of migration were reported as the 
average number of migrated CD4+, CD8+ or HER2/neu specific T cells divided by the 
average loaded live CD3+ cells for that patient and then multiplied by 100.
To block CXCL10 and CXCL12-mediated migration, T cells were pre-stained with anti-
CXCR3 (MAB160, R&D Systems) and anti-CXCR4 antibodies (MAB170, R&D Systems) 
respectively. To block CCL28-mediated migration, anti-CCL28 antibody (MAB717, R&D 
Systems) was directly added to the chemokine containing chamber and incubated at 37° C 
for an hour.
Statistical analysis
Statistical analysis of gene expression and the significance of associations between 
categorical variables were performed using R. Pearson’s χ2-tests. Heat maps and cluster 
analysis of the 8 most highly expressed chemokines in ovarian cancer TMAs were done 
using R. Paired t-test was used to compare chemokine receptor expression and migration 
data. P-values <0.05 were considered statistically significant.
Results
Specific chemokine genes are expressed by advanced ovarian cancer
In order to determine the chemokines that are important in ovarian cancer for T cell homing, 
the expression of all known human chemokines was analyzed on a gene expression array 
dataset from 63 patients with primary ovarian cancer from the University of Turin, and 
validated on a publicly available microarray dataset from 222 ovarian cancer samples from 
the Australian Ovarian Cancer study. Most chemokines were expressed at low levels on 
average in ovarian cancer, although there was significant heterogeneity in the expression 
levels among patients for approximately half of the chemokine genes (Figure 1A–D). The 
five most highly expressed chemokines in both the training and validation datasets were 
CCL2, CCL5, CXCL10, CXCL12 and CXCL16.
We further validated the chemokines expressed by ovarian cancer cells by examining the 
gene expression data of 13 established ovarian cancer cell lines with papillary serous origin. 
We found that few were constitutively expressed in vitro, including CXCL16, CXCL1, 
CX3CL1, CCL17 and CCL28.
Among the chemokines most highly expressed in ovarian cancer in vivo, we found high 
constitutive expression of only CXCL16 in cancer cell lines in vitro, while CXCL10, 
CXCL12, CCL2 and CCL5 were not expressed or were expressed at low levels (Figure 1E, 
F). Thus, ovarian tumors express specific chemokines, and their expression seems to be 
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associated with in vivo tumor conditions rather than being a constitutive feature of ovarian 
cancer cells.
Ovarian cancers express quasi-universal chemokines
Next, we validated the chemokine expression by immunohistochemistry using commercially 
available antibodies on an ovarian serous carcinoma tissue microarray from an independent 
cohort of 50 patients from UPENN (Table 1). This patient cohort was similar to the two 
previous cohorts of patients analyzed by Affymetrix arrays: the most important clinical 
factors associated with survival (age, stage of disease, tumor grade, and ratio of optimally/
suboptimally debulked patients) were not statistically different among the three cohorts, and 
all cohorts received standard adjuvant chemotherapy that reflected the best current practice. 
All samples were collected during primary surgery from chemotherapy-naïve patients. We 
selected for validation the chemokine genes with the most high and/or prevalent expression 
in any of the three above microarray datasets, as well as chemokines with expression level 
showing large variation across patients. This final list included 9 chemokines: CCL2, CCL4, 
CCL5, CCL28, CXCL1, CXCL10, CXCL12, CXCL16 and CX3CL1. With the exception of 
CXCL1 (where staining with all the commercially available antibodies appeared to be 
nonspecific), staining of the selected chemokines was successfully titrated and validated on 
positive and negative control tissues prior to immunohistochemical analysis of the TMA 
samples. To associate the expression of the above chemokines with the presence of effector 
cytotoxic lymphocytes (CTLs) and Treg cells at the time of diagnosis, TMA samples were 
also stained for CD3, CD8 and FoxP3 (Figure 2A). Median expression levels of chemokines 
and T cells were correlated at primary and metastatic sites (Figure 2E).
Immunohistochemistry confirmed the expression of all above chemokines at the protein 
level in ovarian cancer (Figure 2B). Importantly, expression of all chemokines was 
confirmed within tumor islets in association with the tumor cells. In addition, expression of 
the same chemokines was found at both primary and metastatic sites, indicating high degree 
of similarities among sites with no statistical staining differences for any of these 
chemokines (Figure 2C).
However, there was heterogeneity of chemokine expression among samples. This 
heterogeneity was mostly restricted to CCL2, CCL4, CCL5, CCL28 and CX3CL1, which 
showed no expression in a proportion of patients (Figure 2C). On the other hand, we could 
identify a group of chemokines that appeared to be quasi-universally expressed in ovarian 
cancer (CXCL10, CXCL12, CXCL16) (Figure 2C). Based on the median expression, the 
calculated mean H-score for chemokine staining was the highest for CXCL10, CXCL12 and 
CXCL16, demonstrating that these chemokines showed the strongest staining and stained 
the highest percentage of ovarian cancer tissue (Figure 2D).
Tumors with intraepithelial T cells expressed many of the prior mentioned variable 
chemokines: CCL2, CCL4, CCL5, CCL28 and CX3CL1, and in addition, they expressed 
most of the quasi-universal chemokines CXCL10, CXCL12 and CXCL16. The expression of 
CCL4 and CCL5 showed the strongest correlation with the presence of tumor-infiltrating 
CD8+ cells, whereas CCL4, CX3CL1 and CXCL12 expression showed correlation with 
increased numbers of FoxP3+ cells in tumor islets (correlation 0.4–0.5) in the primary tumor 
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tissues (Figure 2E). In addition, CCL28 and CXCL16 were correlated with FoxP3+ cells 
present in the stromal tumor tissue. These data are in agreement with previous observations 
(2, 27, 28). Importantly, the above correlations were substantially reduced or lost in the 
metastatic tumor sites (Figure 2E).
Vaccine-primed and costimulated T cells used in adoptive therapy express appropriate 
receptors for ovarian cancer chemokines
Based on the above data, we hypothesized that ovarian cancers express ligands for the 
following chemokine receptors: CCR1, CCR2, CCR3, CCR4, CCR5, CCR10, CXCR3, 
CXCR4, CXCR6, CX3CR1 (Figure 3A). We thus asked whether our two immunotherapy 
protocols, i.e. the whole tumor lysate-pulsed DC vaccine approach (UPCC-19809 protocol) 
and the following adoptive transfer of ex vivo CD3/CD28 costimulated vaccine-primed 
peripheral blood T cells (UPCC-26810 protocol), generate T cells expressing the appropriate 
chemokine receptors for being attracted by the ovarian cancer chemokine microenvironment. 
In protocol UPCC-19809, vaccine-primed peripheral blood T cells were collected through 
apheresis and elutriation following 4–5 vaccinations. A portion of these vaccine-primed cells 
was then subjected to ex vivo costimulation and expansion using anti-CD3/anti-CD28 Ab 
coated beads, in preparation for adoptive transfer to the same patient. As expected, CD3/
CD28 costimulation resulted in preferential expansion of CD4+ cells compared to the 
apheresis samples (79% SD=13.7 vs. 59% SD=21.4 of total CD3+ cells, respectively, not 
shown). We analyzed the expression of the above chemokine receptors by flow cytometry in 
matched samples of vaccine-primed peripheral blood CD4+ and CD8+ cells T cells collected 
at the completion of vaccination and following ex vivo expansion with CD3/CD28-coated 
beads from five HLA A*0201+ subjects (Figure 3B and C). Figures 3D and E show 
representative examples of FACS analysis and staining specificity.
In peripheral blood CD4+ T cells collected following vaccination the most commonly 
expressed chemokine receptors were CCR10 (CCL27 and CCL28 receptor), expressed on 
48.5% (SD=17.1) of cells; CXCR3 (CXCL9-11 receptor), expressed on 19.8% (SD=17.5) of 
cells; CXCR4 (CXCL12 receptor), expressed on 8.5% (SD=5.4) of cells; and CCR4 (CCL2, 
CCL4, CCL5, CCL17 and CCL22 receptor), expressed on 19.4% (SD=7.7) of cells (Figure 
3C). A low proportion (5.5% (SD=4.4)) of vaccine-primed CD4+ cells also expressed CCR5 
(CCL3, CCL4 and CCL5 receptor). Vaccine-primed CD8+ cells similarly expressed CCR10 
(77.3% SD=12.7), CXCR3 (21.8% SD=8.2), CXCR4 (9.3% SD=13.7) and CCR5 (13.3% 
SD=11.4) (Figure 3D). CCR1, CCR2, CCR3, CXCR2, CXCR6, CX3CXR1 receptors were 
all expressed at very low levels in vaccine-primed elutriated peripheral CD4+ and CD8+ T 
cells. In addition, CCR4 expression in the CD8+ cell population was low (7.4%, SD=5.7).
Interestingly, CD3/CD28 costimulation induced a significant upregulation in CXCR3 and 
CXCR4 expression as well as the number of CD4+ and CD8+ cells expressing these 
receptors.. Specifically, 40–75% of CD4+ and CD8+ cells expressed CXCR3 and CXCR4, 
compared to 8–21% of the peripheral vaccine primed T cells. The receptor density for 
CXCR3 and CXCR4 also increased on the cells expressing these receptors, while the 
receptor density remained stable for CCR10 (Figure 3C, D). Thus, vaccine-primed 
peripheral blood T cells express appropriate chemokines for homing to ovarian cancer, and 
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costimulation increases expression of relevant receptors (both receptor density and number 
of cells) to quasi-universal ovarian cancer chemokines.
CD3/CD28 costimulation enhances migration of vaccine-primed peripheral blood T cells to 
ovarian cancer chemokines
Next, we tested whether peripheral blood T cells collected directly from vaccinated subjects 
or following ex vivo costimulation can migrate towards chemokine ligands cognate to the 
most highly expressed chemokine receptors, CCR10, CXCR3 and CXCR4. We chose 
CCL28, CXCL10 and CXCL12 as the cognate chemokines.
Considering vaccine-primed peripheral blood T cells, CCL28 (at 10 ng/ml) exerted a modest 
chemoattractant effect on bulk CD4+ and minimal effect on CD8+ cells, while CXCL10 (at 
50 ng/ml) recruited both CD4+ and CD8+ cells (Figure 4A). Migration of bulk CD4+ as well 
as CD8+ cells was highest in the presence of CXCL12 (100 ng/ml). Blocking antibodies 
reversed the pro-migratory effect of all 3 chemokines. The combination of chemokines did 
not enhance significantly the recruitment of T cells relative to individual chemokines, and 
most of the migration was attributed to the presence of CXCL12, which recruited the largest 
population of T cells.
CD3/CD28 costimulation enhanced the baseline motility of T cells and, importantly, induced 
a 2-fold increase in chemotaxis to CXCL10 and a 4-fold increase in chemotaxis to CXCL12 
compared to non-costimulated elutriated T cells, both in CD4+ and CD8+ cells (Figure 4A). 
This increase was consistent with CXCR3 and CXR4 upregulation in these cells. Thus, 
costimulation appears to enhance the homing ability of vaccine-primed T cells towards the 
chemokines expressed in the ovarian tumor microenvironment. Supplementary Figure 1 
shows an example of FACS analysis from one patient’s sample.
Tumor-specific T cells respond to chemokines expressed in ovarian cancer
Finally, we analyzed whether tumor-specific T cells elicited by the DC vaccine in protocol 
UPCC-19809 or the same T cells costimulated and expanded with CD3/CD28 in protocol 
UPCC-26810 migrated towards the cognate ovarian cancer chemokines. Costimulation of 
vaccine-primed T cells increased their migration toward the quasi-universal ovarian cancer 
chemokines (CXCL10, CXCL12, CCL28) compared to non-costimulated vaccine-primed T 
cells. We previously reported that advanced ovarian cancers ubiquitously express the 
Her2/neu protein (25) and that the DC based whole tumor lysate vaccine elicits T cells 
directed against known HLA-A*0201 restricted epitopes (7). We thus tested whether among 
T cells attracted by the quasi-universal ovarian cancer chemokines we could identify 
pentamer-positive T cells specific to A*0201-restricted Her2/neu peptide 369–377. HER2/
neu-specific T cells were detected both in the vaccine primed and expanded T cell 
population. Expanded HER2/neu-specific T cells migrated the most in the presence of all 
three chemokines (CCL28+CXCL10+CXCL12) compare to baseline (T cell only). Due to 
the very low frequency of these cells we are only able to show the absolute number of 
migrated tumor specific cells among the loaded live CD3+ cells (Figure 4B). Additional 
studies with more patient samples are needed to further validate these findings.
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Discussion
Ovarian cancer patients with pre-existing CD3+ or CD8+ intraepithelial T cells (TILs) at the 
time of diagnosis live significantly longer (1), suggesting that activation of antitumor 
immunity can enhance their survival. To test this hypothesis, we are conducting two related 
clinical studies, in which patients with recurrent ovarian cancer undergo vaccination with 
DC in combination with bevacizumab and low dose cyclophosphamide, followed by 
adoptive transfer of CD3/CD28 costimulated vaccine-primed T cells. Although in patients 
with pre-existing TILs it is intuitive that lymphocytes elicited by the vaccine or transferred 
adoptively should be able to home to tumors, such assumption may not be justified in 
patients lacking pre-existing T cells, since their tumor at the steady state may not have the 
necessary conditions for lymphocyte homing. As chemokines can regulate immune cell 
trafficking, we sought to understand the chemokine microenvironment of ovarian cancer and 
test whether this environment can support the homing of effector lymphocytes generated 
with cell-based immunotherapy.
Although the overall ovarian cancer chemokine landscape was found to be quite 
heterogeneous with high expression of known lymphocyte-recruiting chemokines in tumors 
with TILs, few chemokines such as CXCL10, CXCL12 and CXCL16, were expressed quasi-
universally, including in tumors with T cells in the stroma but lacking TILs. We also 
observed high expression of CXCL1 mRNA in all three gene expression data sets, however 
could not validate its presence at the protein level due to the lack of reliable commercial 
antibodies. CXCL1 is a highly pro-angiogenic ELR+ chemokine (29), which mainly recruits 
neutrophils and thus could be less relevant with respect to T cell homing. Importantly, and 
with relevance to immune therapy, CXCL10, CXCL12 and CXCL16, are important 
lymphocyte chemoattractants. Their expression was localized to the epithelial component of 
the tumor, i.e. in association with tumor cells, and it was preserved across all metastatic 
sites, suggesting that T cells elicited by immunotherapy can home to the tumor cell 
compartment and potentially to all metastatic deposits.
The expression of T cell-recruiting chemokines by cancer cells could appear paradoxical. 
For example, although tumor derived CXCL12 has been reported to attract T cells (30), (31) 
it also exerts important tumor-promoting functions. In fact, CXCL12 and CXCL16 are 
overexpressed in epithelial ovarian carcinomas (32, 33), and other solid tumors (34, 35). 
CXCL12 is a powerful activator of the MAP kinase cascade in ovarian cancer cells. Cross-
talk between the CXCL12/CXCR4 and the EGFR pathways promotes ovarian cell 
proliferation (36) and CXCL12/CXCR4 expression is associated with peritoneal metastasis 
and ascites formation (36, 37). High CXCL16 expression has also been correlated with poor 
prognosis in colorectal and prostate cancer (38, 39). Unlike CXCL10 and CXCL12, which 
were expressed only in vivo, CXCL16 seems constitutively activated in ovarian cancer cells, 
as it was also detected in primary and established cell lines in vitro. This could be driven in 
part by the commonly activated Akt/mTOR pathway (40, 41).
Although CXCL10, CXCL12 and CXCL16 are known to recruit T cells, their expression did 
not correlate with T cell infiltration in ovarian tumor islets at the time of diagnosis. In fact, 
approximately half of the tumors did not exhibit intraepithelial T cells, in agreement with 
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our previous observations (1), despite expressing one or more of these chemokines. This 
could raise the possibility that such chemokines in fact do not contribute to recruiting T 
cells. For example, tumors can secrete an antagonistic N-terminally cleaved CXCL10 
variant, which leads to early impairment of the immune response (42). CXCL12 expression 
by tumor fibroblasts was recently associated with lack of T cells in a pancreatic 
adenocarcinoma model, while the use of a CXCR4 small molecule inhibitor ameliorated T 
cell homing to tumors and tumor immune attack (43). It was hypothesized that CXCL12 
bound on tumor cells through CXCR4 could directly eliminate tumor-reactive T cells. 
CXCL12 can also recruit suppressive plasmacytoid DCs to ovarian cancer (44) and we 
found a correlation of CXCL12 expression with the presence of Treg cells. These are 
indirect CXCL12-dependent mechanisms, which could drive peripheral tolerance through 
deregulation of tumor antigen presentation or attenuation of tumor-reactive T cells. 
Furthermore, CXCR4 ligation may downregulate tumor cell MHC-I expression (45) leading 
to the inability of T cells to recognize the tumor and engraft in tumor islets (46).
Additional mechanisms to prevent T cell homing and engraftment are likely to operate in 
these tumors. For example, we have described the tumor endothelial barrier, which prevents 
T cell extravasation in tumors in part due to endothelin B receptor-mediated downregulation 
of endothelial ICAM-1 expression (47), and through the upregulation of death-inducing 
molecules on surface endothelium such as Fas ligand (48). In addition, tumor derived 
soluble factors and surface inhibitory ligands can attenuate T cell function, further 
preventing their engraftment (49). Successful immunotherapy must address these multiple 
mechanisms to maximize clinical efficacy.
A small fraction of peripheral blood CD4+ and CD8+ T cells from ovarian cancer patients 
vaccinated with DC vaccine expressed chemokine receptors to the quasi-universal 
chemokines CXCL10 (CXCR3) and CXCL12 (CXCR4) and a higher fraction of peripheral 
blood CD4+ and CD8+ T cells expressed CCR10, the receptor for CCL28. In addition, a 
small fraction expressed CCR4 and CCR5, the receptors for heterogeneous ovarian cancer 
chemokines such as CCL2, CCL4 and CCL5. Thus, peripheral blood CD4+ and CD8+ T 
cells have the potential ability to traffic to ovarian cancer sites, which was corroborated by 
chemotaxis experiments, demonstrating migration towards recombinant CCL28, CXCL10, 
or CXCL12 alone or combined with the above. Among vaccine-primed T cells migrating 
towards the above cytokines, we found CD8+ T cells specific to the Her2/neu peptide 369–
377, which as we demonstrated previously, are undetectable at base line and are specifically 
induced by DC-lysate vaccine (4, 7). Importantly, CD3/CD28 costimulation induced a 
significant upregulation of CXCR3 and CXCR4 in both CD4+ and CD8+ T cells from 
vaccine-primed peripheral blood T cells. We believe this enhanced migration in the CD3/
CD28 costimulated cells was mainly attributed to upregulated CXCR3 and CXCR4 
receptors however, it is known that activated T lymphocytes undergo a metabolic 
reprogramming with increased aerobic glycolysis and comparatively low rates of oxidative 
phosphorylation, factors that could also contribute to migration (50)
In summary, we demonstrate that ovarian cancers express a variety of lymphocyte recruiting 
chemokines. Tumors with pre-existing intraepithelial T cells express high levels of CCL4, 
CCL5 or CCL8, which can recruit vaccine-primed T cells expressing CCR5 or CCR10. The 
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expression of CCL4 and CCL5, which bind to CCR1, CCR3, CCR5 and CCR4, showed the 
strongest correlation with the presence of tumor-infiltrating CD8+ T cells. One could 
hypothesize that upregulation of CCR5, CCR4 and CCR3 in ex vivo CD3/CD28 activated 
vaccine primed T cells could improve tumor homing in cancers expressing CCL4 and CCL5. 
In addition, these tumors express also one or more of the quasi-universal chemokines 
CXCL10 and CXCL12, which could recruit relevant vaccine-primed tumor-reactive T cells 
expressing CXCR3 or CXCR4. Given the ability of these tumors to recruit T cells at 
baseline, and based on their chemokine repertoire, these tumors are predictably readily 
infiltrated by vaccine-primed or ex vivo costimulated T cells. On the other hand, tumors 
lacking pre-existing T cells were found to express one or both of the quasi-universal 
lymphocyte recruiting chemokines CXCL10 and CXCL12. T cells elicited by DC vaccine 
expressed the appropriate receptors to home to these chemokines, and ex vivo CD3/CD28 
costimulation further enhanced expression of these chemokine receptors and migration 
towards these chemokines. Further work is required to assess whether CXCL12 or CXCL10 
can promote or rather suppress recruitment of T cells in tumors lacking intraepithelial T 
cells, but additional factors could certainly prevent T cell homing and function in these 
tumors. In our clinical trial design the addition of vascular normalization with bevacizumab 
and the attenuation of Treg with low dose cyclophosphamide are addressing two such 
important factors. Immunotherapy approaches that can expand the available pool of tumor-
reactive T cells such as vaccines and adoptive transfer of vaccine-primed T cells could 
obviate the lack of intraepithelial T cells in many ovarian cancers. The ongoing studies with 
the tumor lysate-pulsed DC vaccine and adoptive transfer of vaccine-primed costimulated T 
cells will provide us an opportunity to test this hypothesis.
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Translational Relevance
Chemokines are key regulators of circulation, homing and retention of T cells, thus the 
characterization of the tumor microenvironment chemokine milieu is key to developing 
effective immunotherapy against solid tumors. Our data show that DC-primed and ex 
vivo CD3/CD28 costimulated peripheral blood T cells are endowed with appropriate 
chemokine receptors and show enhanced migration towards commonly expressed 
chemokines in ovarian cancer.
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Figure 1. Chemokine expression in ovarian cancer
A and B: Gene expression analysis of chemokines in the training cohort (A) and in the 
validation cohort (B), showing the median expression and the four quartiles with the outliers 
presented as individual circles. C and D: Heat map generated from the training cohort (C: 
n=63) and the validation cohort (D: n=222) showing the individual patients’ chemokine 
expression level for the top 20 most highly expressed chemokines from both data sets. Color 
code shows the expression level compared to the mean gene expression, where the white 
color shows the mean expression level for all genes. E: Gene expression analysis of all 
known chemokines on 13 papillary serous ovarian cancer cell lines, showing the median 
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expression and the four quartiles with the outliers presented as individual circles. F: Heat 
map generated from the 13 ovarian cancer cell lines showing each cell line separately with 
the expression level for all known chemokines.
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Figure 2. Correlation of chemokine expression and infiltration of CD8+ and FoxP3+ T cells in 
ovarian cancer
A: Representative images of papillary serous ovarian cancer specimens that stained strongly 
positive for chemokine expression (20X). B: Representative images of staining for CD8 and 
FoxP3 (20X). C: Heterogeneity heat map demonstrating the median H-score calculated for 
every single evaluable tumor core. The first two rows represent tumor samples from the 
primary disease site (ovaries), while the last 4 rows represent tumor samples from available 
metastatic sites. Missing values are coded with white. D: Heat map demonstrating the 
average median H-scores from all sites (ovaries and metastasis combined) calculated for 
every patient sample on TMA. E: Heat map showing the correlation between chemokine 
expression and CD8+ and FoxP3+ cells at the primary and metastatic site.
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Figure 3. Chemokine receptor expression on vaccine-primed and CD3/CD28 costimulated CD4+ 
and CD8+ T cells
A: Table showing the most highly expressed chemokines from the 3 microarray data set 
selected for staining with their matching chemokine receptors. B and C: Chemokine 
receptor expression on peripheral blood vaccine-primed peripheral blood CD4+ (B) and 
CD8+ T cells (C) at the steady state and after ex vivo CD3/CD28 costimulation. CD4+ cells 
mainly express CCR4, CCR10, CXCR3 and CXCR4 receptors. The number of CD4+ T cells 
expressing CCR10 was significantly decreased, while the number of cells expressing 
CXCR3 and CXCR4 was significantly increased by CD3/CD28 costimulation. CD8+ cells 
mainly express CCR10, CXCR3 and CXCR4 receptors. The number of CD8+ T cells 
expressing CXCR3 and CXCR4 was significantly increased by CD3/CD28 costimulation. 
(*p<0.05, **p<0.01). D: Representative FACS figures of CCR10, CXCR3 and CXCR4 
receptor density expression on the different cell types. E: Representative FACS figures 
showing CXCR3 and CXCR4 before and after the blockade with specific antibodies.
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Figure 4. Chemokine-induced migration of vaccine-primed and CD3/CD28 costimulated HER2/
neu369–377 specific T cells
A: Chemotaxis of CD4+ and CD8+ T cells T cells in the presence of tested chemokines. 
CCD3/CD28-costimulated T cells show increased migration even at baseline compared to 
vaccine primed T cells. In both CD4+ and CD8+ cells CCL28 induced very little migration 
compared to baseline chemotaxis measured in the T cell only group. CXCL10 induced 
slightly increased migration in the CD4+ cell population; however it was not statistically 
significant. CXCL12 induced significantly increased migration compared to baseline. Also 
the CD3/CD28 costimulated T cells migrated significantly more in the presence of CXCL12 
compared to elutriated T cells. The various combination of chemokines only induced strong 
migration if CXCL12 was present, and the addition of CCL28 and CXCL10 did not further 
enhance chemotaxis. * p<0.05 B: Migration of HER2/neu369–377 positive cells in the 
presence of various chemokines. Her2/ neu369–377 positive cells were detected in both the 
elutriated and the adoptive T cell population and also showed enhanced migration in the 
presence of CXCL12.
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